Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.
Q2 FY26 Earnings Results
-
Revenue from Operations: ₹3,697.16 crore, up 20.77% YoY and 3.55% QoQ.
-
EBITDA: ₹924 crore, with an EBITDA margin of 25.0%, representing an 8.7% YoY increase.
-
Profit After Tax (PAT): ₹520 crore, down 21.5% YoY but up 16.7% QoQ.
-
PAT margin: Approximately 14.1%.
-
Domestic revenue rose 14.5% YoY to ₹3,184 crore.
-
Exports surged 82.6% YoY, boosted by integration of Bharat Serums and Vaccines (BSV).
-
Chronic segment saw strong performance with 1.3x growth in Cardiac and 1.2x in Anti-Diabetics.
-
Consumer healthcare revenue declined 3% YoY, affected by supply chain issues and uneven monsoon.
Management Commentary & Strategic Decisions
-
Vice Chairman & MD Rajeev Juneja highlighted strong growth led by chronic segment and BSV integration, with short-term challenges in consumer healthcare due to GST disruptions and monsoon impact.
-
Focus on synergy realization from BSV acquisition to enhance revenue and cost efficiencies.
-
Management emphasized sustained volume growth, market share gains, and a robust product pipeline including vaccines and biologics.
-
Confident on long-term growth despite near-term margin pressures and external challenges.
Q1 FY26 Earnings Results
-
Revenue from Operations: ₹3,570.35 crore, up 24.4% YoY from ₹2,867.85 crore in Q1 FY25.
-
Profit After Tax (PAT): ₹445 crore, down 18% YoY.
-
EBITDA: ₹850 crore, with margin improving marginally to 23.8%.
-
Strong growth in chronic and export businesses; consumer segment also showed growth.
-
Increased costs in employee expenses, R&D, and raw materials impacted margins.
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.